Albeit not investigated in neuroblastoma, studies in solid tumors show that the axis can be disrupted either by inhibiting CCR2 [168,169] or via anti-CCL2 antibodies [170,171,172], thereby preventing the recruitment of suppressive myeloid cells and initiation of their tumor-promoting effects. The gene discussed is CCL2; the disease is neoplasm.